Literature DB >> 15227332

Stroke and the total artificial heart: neurologic considerations.

R G Hart1, D G Sherman.   

Abstract

Neurologic complications, particularly brain infarction (ischemic stroke), are frequent and serious sequelae of total artificial heart (TAH) implantation. Most strokes that occur in TAH patients are due to embolism of thrombotic fragments originating on prosthetic surfaces. The emboli tend to lodge in the middle cerebral artery or its cortical branches and cause cortical syndromes. Cardioembolic strokes are characteristically heralded by the abrupt onset of a maximal neurologic deficit in an awake, often active patient. Cardioembolic strokes have a tendency to undergo hemorrhagic transformation. Anticoagulation is a major issue in stroke management: In anticoagulated patients, hemorrhagic transformation often results in major neurologic worsening; therefore, this risk must be weighed against the danger of recurrent embolism in the absence of anticoagulation. We recommend avoiding anticoagulation during the initial 24 to 48 hours after a stroke, especially in patients with large cardioembolic infarcts. Because of the many invasive procedures producing bacteremia in TAH patients, combined with the large area of prosthetic surfaces, infective endocarditis is a potential concern. Weighing the risks and benefits of anticoagulation in patients with infective endocarditis is likely to produce a controversial choice. Anticoagulation should probably be continued in such patients if they have total artificial hearts. The following article discusses the foregoing issues and presents recommendations for managing acute stroke in TAH patients.

Entities:  

Year:  1987        PMID: 15227332      PMCID: PMC324695     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  9 in total

1.  Hemorrhagic infarcts.

Authors:  R G Hart; J D Easton
Journal:  Stroke       Date:  1986 Jul-Aug       Impact factor: 7.914

2.  Prosthetic valve endocarditis.

Authors:  P C Block; R W DeSanctis; A N Weinberg; W G Austen
Journal:  J Thorac Cardiovasc Surg       Date:  1970-10       Impact factor: 5.209

3.  Infective endocarditis--an evolving disease. A review of endocarditis at the Columbia-Presbyterian Medical Center, 1968-1973.

Authors:  G J Garvey; H C Neu
Journal:  Medicine (Baltimore)       Date:  1978-03       Impact factor: 1.889

4.  Anticoagulant therapy and central nervous system complications in patients with prosthetic valve endocarditis.

Authors:  W R Wilson; J E Geraci; G K Danielson; R L Thompson; J A Spittell; J R Washington; E R Giuliani
Journal:  Circulation       Date:  1978-05       Impact factor: 29.690

5.  Late prosthetic valve endocarditis: clinical features influencing therapy.

Authors:  A W Karchmer; W E Dismukes; M J Buckley; W G Austen
Journal:  Am J Med       Date:  1978-02       Impact factor: 4.965

6.  Intracranial hemorrhage and infarction in anticoagulated patients with prosthetic heart valves.

Authors:  A Lieberman; W K Hass; R Pinto; W O Isom; M Kupersmith; G Bear; R Chase
Journal:  Stroke       Date:  1978 Jan-Feb       Impact factor: 7.914

7.  Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.

Authors:  F Van de Werf; P A Ludbrook; S R Bergmann; A J Tiefenbrunn; K A Fox; H de Geest; M Verstraete; D Collen; B E Sobel
Journal:  N Engl J Med       Date:  1984-03-08       Impact factor: 91.245

8.  Anticoagulation in prosthetic valve endocarditis.

Authors:  J L Carpenter; C K McAllister
Journal:  South Med J       Date:  1983-11       Impact factor: 0.954

9.  Management of complications of infective endocarditis.

Authors:  W R Wilson; E R Giuliani; G K Danielson; J E Geraci
Journal:  Mayo Clin Proc       Date:  1982-03       Impact factor: 7.616

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.